FY2026 Earnings Estimate for Q32 Bio Issued By HC Wainwright

Key Points

• HC Wainwright raised its FY2026 loss estimate for Q32 Bio to $1.38 per share from $1.56, while maintaining a Buy rating and a $36 price target. The revised estimate is narrower than the $1.54-per-share loss consensus.
• Q32 Bio reported a quarterly loss of $0.26 per share, beating analyst expectations of a $0.33 loss by $0.07.
• Analyst sentiment is broadly positive: Q32 Bio has a consensus rating of “Moderate Buy” and an average price target of $32.17.

Q32 Bio Inc. (NASDAQ:QTTB - Free Report) - Equities research analysts at HC Wainwright boosted their FY2026 earnings estimates for shares of Q32 Bio in a report issued on Wednesday, November 4th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($1.38) per share for the year, up from their previous estimate of ($1.56). HC Wainwright has a "Buy" rating and a $36.00 price target on the stock. The consensus estimate for Q32 Bio's current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for Q32 Bio's Q4 2026 earnings at ($0.29) EPS, FY2027 earnings at ($1.22) EPS, FY2028 earnings at ($1.27) EPS, FY2029 earnings at $0.94 EPS and FY2030 earnings at $2.36 EPS.

Q32 Bio (NASDAQ:QTTB - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.07.

A number of other research analysts have also recently commented on QTTB. Jefferies Financial Group initiated coverage on Q32 Bio in a report on Monday, September 28th. They issued a "buy" rating and a $29.00 price target on the stock. Mizuho raised shares of Q32 Bio to a "strong-buy" rating in a report on Monday, September 7th. Oppenheimer reiterated an "outperform" rating on shares of Q32 Bio in a research report on Thursday, October 1st. Morgan Stanley started coverage on shares of Q32 Bio in a report on Monday, August 24th. They issued an "overweight" rating and a $34.00 target price on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Q32 Bio in a research report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Q32 Bio currently has an average rating of "Moderate Buy" and a consensus price target of $32.17.

Q32 Bio Stock Down 1.3%

NASDAQ QTTB opened at $8.85 on Friday. Q32 Bio has a twelve month low of $1.90 and a twelve month high of $23.57. The business has a 50-day moving average price of $9.86 and a 200-day moving average price of $9.33. The firm has a market cap of $263.46 million, a price-to-earnings ratio of 2.65 and a beta of 0.45.

Institutional Investors Weigh In On Q32 Bio

Several large investors have recently bought and sold shares of the business. Atlas Venture Life Science Advisors LLC lifted its position in Q32 Bio by 29.9% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,717,106 shares of the company's stock valued at $34,616,000 after purchasing an additional 625,000 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Q32 Bio in the 2nd quarter worth about $1,510,000. Renaissance Technologies LLC increased its holdings in shares of Q32 Bio by 107.7% in the 1st quarter. Renaissance Technologies LLC now owns 206,915 shares of the company's stock worth $1,328,000 after buying an additional 107,315 shares during the last quarter. Carlyle Group Inc. purchased a new stake in shares of Q32 Bio during the 2nd quarter valued at about $769,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Q32 Bio during the 2nd quarter valued at about $303,000. Institutional investors own 31.32% of the company's stock.

Insider Activity at Q32 Bio

In other Q32 Bio news, CEO Jodie Morrison sold 9,845 shares of Q32 Bio stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total value of $163,033.20. Following the sale, the chief executive officer owned 343,259 shares of the company's stock, valued at $5,684,369.04. The trade was a 2.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia M. Violette sold 2,798 shares of the company's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total value of $46,334.88. Following the sale, the insider directly owned 127,771 shares in the company, valued at $2,115,887.76. This trade represents a 2.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 22,054 shares of company stock valued at $320,397. Insiders own 34.46% of the company's stock.

Q32 Bio Company Profile

Q32 Bio Inc NASDAQ: QTTB is a clinical-stage biotechnology company focused on developing biologic therapies for diseases associated with immune-system dysfunction. The company's research programs are designed to restore immune balance rather than broadly suppress immune activity.

Q32 Bio's lead product candidate is bempikibart, formerly known as ADX-914, a fully human monoclonal antibody that targets activin receptor type IIA (ActRIIA). The company has evaluated bempikibart in inflammatory and autoimmune conditions, including atopic dermatitis and alopecia areata.

The company also has pursued additional immunology programs, including therapies intended to address complement-mediated disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.